NASDAQ:KRTX Karuna Therapeutics (KRTX) Stock Forecast, Price & News $164.66 -1.37 (-0.83%) (As of 09/25/2023 ET) Add Compare Share Share Today's Range$162.61▼$167.7150-Day Range$164.66▼$206.8352-Week Range$159.73▼$245.00Volume277,778 shsAverage Volume352,677 shsMarket Capitalization$6.20 billionP/E RatioN/ADividend YieldN/APrice Target$260.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Karuna Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside58.2% Upside$260.50 Price TargetShort InterestHealthy3.58% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.23Based on 5 Articles This WeekInsider TradingSelling Shares$6.70 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($11.04) to ($10.94) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.74 out of 5 starsMedical Sector82nd out of 962 stocksBiotechnology Industry1st out of 11 stocks 4.4 Analyst's Opinion Consensus RatingKaruna Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 10 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $260.50, Karuna Therapeutics has a forecasted upside of 58.2% from its current price of $164.66.Amount of Analyst CoverageKaruna Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.58% of the outstanding shares of Karuna Therapeutics have been sold short.Short Interest Ratio / Days to CoverKaruna Therapeutics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Karuna Therapeutics has recently decreased by 6.90%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldKaruna Therapeutics does not currently pay a dividend.Dividend GrowthKaruna Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KRTX. Previous Next 3.5 News and Social Media Coverage News SentimentKaruna Therapeutics has a news sentiment score of 1.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Karuna Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 2 people have searched for KRTX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows5 people have added Karuna Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Karuna Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,697,791.00 in company stock.Percentage Held by Insiders13.20% of the stock of Karuna Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Karuna Therapeutics are expected to grow in the coming year, from ($11.04) to ($10.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Karuna Therapeutics is -16.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Karuna Therapeutics is -16.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKaruna Therapeutics has a P/B Ratio of 5.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Karuna Therapeutics (NASDAQ:KRTX) StockKaruna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of mood and anxiety disorders. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Read More KRTX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KRTX Stock News HeadlinesSeptember 22, 2023 | finance.yahoo.comWhat Makes Karuna Therapeutics (KRTX) a Prospective Investment?September 19, 2023 | americanbankingnews.comShort Interest in Karuna Therapeutics, Inc. (NASDAQ:KRTX) Drops By 6.9%September 25, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...September 17, 2023 | americanbankingnews.comKaruna Therapeutics, Inc. (NASDAQ:KRTX) Given Average Rating of "Moderate Buy" by BrokeragesSeptember 12, 2023 | finance.yahoo.comChief Medical Officer Stephen Brannan Sells 5,000 Shares of Karuna Therapeutics Inc (KRTX)September 9, 2023 | msn.comB of A Securities Maintains Karuna Therapeutics (KRTX) Buy RecommendationAugust 30, 2023 | finance.yahoo.comHalf Year 2023 PureTech Health PLC Earnings CallAugust 24, 2023 | seekingalpha.comKaruna: NDA Filing Q3 Of 2023 And Expanded Potential With KarXTSeptember 25, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...August 23, 2023 | msn.comCantor Fitzgerald Reiterates Karuna Therapeutics (KRTX) Neutral RecommendationAugust 23, 2023 | msn.comWells Fargo Initiates Coverage of Karuna Therapeutics (KRTX) with Overweight RecommendationAugust 22, 2023 | msn.comWells Fargo starts Karuna at overweight, cites schizophrenia drug candidateAugust 22, 2023 | markets.businessinsider.com10 Analysts Have This to Say About Karuna TherapeuticsAugust 22, 2023 | markets.businessinsider.comKaruna Therapeutics (KRTX) Initiated with a Buy at Wells FargoAugust 16, 2023 | msn.comKaruna's Robust Liquidity Paves Way For KarXT Milestones (Rating Upgrade)August 9, 2023 | investing.comThis online marketplace stock has been added to Citi's value creators focus listAugust 6, 2023 | fool.comKaruna Therapeutics (NASDAQ: KRTX)August 5, 2023 | msn.comMorgan Stanley Reiterates Karuna Therapeutics (KRTX) Overweight RecommendationAugust 4, 2023 | markets.businessinsider.comH.C. Wainwright Remains a Buy on Karuna Therapeutics (KRTX)August 4, 2023 | markets.businessinsider.comKaruna Therapeutics (KRTX) Receives a Buy from Mizuho SecuritiesAugust 4, 2023 | finance.yahoo.comKaruna Therapeutics Second Quarter 2023 Earnings: US$2.75 loss per share (vs US$2.17 loss in 2Q 2022)August 4, 2023 | finance.yahoo.comKaruna (KRTX) Reports Narrower-Than-Expected Loss in Q2August 3, 2023 | finance.yahoo.comKaruna Therapeutics, Inc. (KRTX) Reports Q2 Loss, Lags Revenue EstimatesAugust 3, 2023 | finance.yahoo.comKaruna Therapeutics Announces Leadership AppointmentsAugust 3, 2023 | finance.yahoo.comKaruna Therapeutics Reports Second Quarter 2023 Financial Results and Provides General Business UpdatesJuly 21, 2023 | msn.comMorgan Stanley Initiates Coverage of Karuna Therapeutics (KRTX) with Overweight RecommendationJuly 20, 2023 | markets.businessinsider.comKaruna Therapeutics (KRTX) Receives a Buy from Morgan StanleySee More Headlines Receive KRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Karuna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address KRTX Company Calendar Last Earnings8/03/2023Today9/25/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KRTX CUSIPN/A CIK1771917 Webkarunatx.com Phone(857) 449-2244FaxN/AEmployees210Year FoundedN/APrice Target and Rating Average Stock Price Forecast$260.50 High Stock Price Forecast$323.00 Low Stock Price Forecast$209.00 Forecasted Upside/Downside+58.2%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($10.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-276,340,000.00 Net Margins-2,795.96% Pretax Margin-5,870.98% Return on Equity-27.13% Return on Assets-26.31% Debt Debt-to-Equity RatioN/A Current Ratio37.61 Quick Ratio37.61 Sales & Book Value Annual Sales$6.01 million Price / Sales1,031.50 Cash FlowN/A Price / Cash FlowN/A Book Value$32.78 per share Price / Book5.02Miscellaneous Outstanding Shares37,668,000Free Float32,696,000Market Cap$6.20 billion OptionableNot Optionable Beta1.06 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Andrew Craig Miller (Age 41)Co-Founder & COO Comp: $835.4kDr. Steven M. Paul M.D. (Age 72)Pres of R&D, Chief Scientific Officer & Director Comp: $1.32MDr. Stephen K. Brannan (Age 67)Chief Medical Officer Comp: $751.75kDr. Troy A. Ignelzi (Age 55)Exec. Officer Comp: $735.95kMr. William Meury (Age 55)Pres, CEO & Director Mr. Jason Parker BrownChief Financial OfficerMs. Mia Kelley J.D.VP of Legal AffairsMr. Jonathan RosinChief HR OfficerDr. Alan BreierChair of Scientific Advisory Board & Chief Clinical AdvisorDr. Ronald N. Marcus M.D. (Age 65)Sr. VP of Medical More ExecutivesKey CompetitorsReata PharmaceuticalsNASDAQ:RETAGrifolsNASDAQ:GRFSIonis PharmaceuticalsNASDAQ:IONSElanco Animal HealthNYSE:ELANAscendis Pharma A/SNASDAQ:ASNDView All CompetitorsInsiders & InstitutionsBarclays PLCBought 37,607 shares on 9/21/2023Ownership: 0.224%Stephen K BrannanSold 5,000 sharesTotal: $920,200.00 ($184.04/share)Jeffrey M JonasSold 13,809 sharesTotal: $2.60 M ($187.93/share)Troy A IgnelziSold 1,500 sharesTotal: $262,680.00 ($175.12/share)Virginia Retirement Systems ET ALBought 5,100 shares on 8/22/2023Ownership: 0.014%View All Insider TransactionsView All Institutional Transactions KRTX Stock - Frequently Asked Questions Should I buy or sell Karuna Therapeutics stock right now? 12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Karuna Therapeutics in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" KRTX shares. View KRTX analyst ratings or view top-rated stocks. What is Karuna Therapeutics' stock price forecast for 2023? 12 Wall Street research analysts have issued 1 year price objectives for Karuna Therapeutics' shares. Their KRTX share price forecasts range from $209.00 to $323.00. On average, they anticipate the company's share price to reach $260.50 in the next year. This suggests a possible upside of 58.2% from the stock's current price. View analysts price targets for KRTX or view top-rated stocks among Wall Street analysts. How have KRTX shares performed in 2023? Karuna Therapeutics' stock was trading at $196.50 on January 1st, 2023. Since then, KRTX shares have decreased by 16.2% and is now trading at $164.66. View the best growth stocks for 2023 here. Are investors shorting Karuna Therapeutics? Karuna Therapeutics saw a drop in short interest during the month of August. As of August 31st, there was short interest totaling 1,350,000 shares, a drop of 6.9% from the August 15th total of 1,450,000 shares. Based on an average trading volume of 345,500 shares, the short-interest ratio is currently 3.9 days. View Karuna Therapeutics' Short Interest. When is Karuna Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our KRTX earnings forecast. How were Karuna Therapeutics' earnings last quarter? Karuna Therapeutics, Inc. (NASDAQ:KRTX) posted its earnings results on Thursday, August, 3rd. The company reported ($2.75) earnings per share for the quarter, beating the consensus estimate of ($2.76) by $0.01. The business earned $0.10 million during the quarter, compared to the consensus estimate of $0.42 million. Karuna Therapeutics had a negative net margin of 2,795.96% and a negative trailing twelve-month return on equity of 27.13%. The firm's revenue was down 98.1% compared to the same quarter last year. During the same quarter last year, the firm posted ($2.17) earnings per share. What ETFs hold Karuna Therapeutics' stock? ETFs with the largest weight of Karuna Therapeutics (NASDAQ:KRTX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Alpha Architect U.S. Quantitative Momentum ETF (QMOM), Principal Healthcare Innovators ETF (BTEC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Biotechnology ETF (IBBQ) and Vanguard Russell 2000 Growth ETF (VTWG). What other stocks do shareholders of Karuna Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Karuna Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), AbbVie (ABBV), Pfizer (PFE), Alibaba Group (BABA), Johnson & Johnson (JNJ), AT&T (T), Target (TGT) and Walt Disney (DIS). When did Karuna Therapeutics IPO? (KRTX) raised $70 million in an initial public offering (IPO) on Friday, June 28th 2019. The company issued 4,400,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Citigroup and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is Karuna Therapeutics' stock symbol? Karuna Therapeutics trades on the NASDAQ under the ticker symbol "KRTX." Who are Karuna Therapeutics' major shareholders? Karuna Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Capital International Investors (10.60%), BlackRock Inc. (4.95%), State Street Corp (2.16%), General Atlantic L.P. (1.93%), Geode Capital Management LLC (1.29%) and Alliancebernstein L.P. (1.02%). Insiders that own company stock include Andrew Craig Miller, Atul Pande, James Healy, Jeffrey M Jonas, Laurie J Olson, Laurie J Olson, Puretech Health Llc, Stephen K Brannan, Steven M Paul and Troy A Ignelzi. View institutional ownership trends. How do I buy shares of Karuna Therapeutics? Shares of KRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Karuna Therapeutics' stock price today? One share of KRTX stock can currently be purchased for approximately $164.66. How much money does Karuna Therapeutics make? Karuna Therapeutics (NASDAQ:KRTX) has a market capitalization of $6.20 billion and generates $6.01 million in revenue each year. The company earns $-276,340,000.00 in net income (profit) each year or ($10.15) on an earnings per share basis. How many employees does Karuna Therapeutics have? The company employs 210 workers across the globe. How can I contact Karuna Therapeutics? Karuna Therapeutics' mailing address is 33 ARCH STREET SUITE 3110, BOSTON MA, 02110. The official website for the company is karunatx.com. The company can be reached via phone at (857) 449-2244 or via email at investors@karunatx.com. This page (NASDAQ:KRTX) was last updated on 9/25/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karuna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.